Cargando…

Multi-site investigation of strategies for the clinical implementation of preemptive pharmacogenetic testing

PURPOSE: The increased availability of clinical pharmacogenetic (PGx) guidelines and decreasing costs for genetic testing have slowly led to increased utilization of PGx testing in clinical practice. Preemptive PGx testing, where testing is performed in advance of drug prescribing, is one means to e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duarte, Julio D., Dalton, Rachel, Elchynski, Amanda L., Smith, D. Max, Cicali, Emily J., Lee, James C., Duong, Benjamin Q., Petry, Natasha J., Aquilante, Christina L., Beitelshees, Amber L., Empey, Philip E., Johnson, Julie A., Obeng, Aniwaa Owusu, Pasternak, Amy L., Pratt, Victoria M., Ramsey, Laura B., Tuteja, Sony, Van Driest, Sara L., Wiisanen, Kristin, Hicks, J. Kevin, Cavallari, Larisa H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633054/ https://www.ncbi.nlm.nih.gov/pubmed/34282303 http://dx.doi.org/10.1038/s41436-021-01269-9

Ejemplares similares

Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy
por: Tuteja, Sony, et al.
Publicado: (2021)

Best–worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy
por: Salloum, Ramzi G., et al.
Publicado: (2022)

Lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan
por: Norris, Madeline, et al.
Publicado: (2023)

Development of Customizable Implementation Guides to Support Clinical Adoption of Pharmacogenomics: Experiences of the Implementing GeNomics In pracTicE (IGNITE) Network
por: Duong, Benjamin Q, et al.
Publicado: (2020)

Reimbursement of pharmacogenetic tests at a tertiary academic medical center in the United States
por: Lemke, Lauren K., et al.
Publicado: (2023)

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real‐World Setting
por: Cavallari, LH, et al.
Publicado: (2017)

Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing
por: Cavallari, Larisa H., et al.
Publicado: (2019)

Utilizing a Human–Computer Interaction Approach to Evaluate the Design of Current Pharmacogenomics Clinical Decision Support
por: Elchynski, Amanda L., et al.
Publicado: (2021)

Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation
por: Lau-Min, Kelsey S., et al.
Publicado: (2022)

A Pharmacogenetics-Based Approach to Managing Gastroesophageal Reflux Disease: Current Perspectives and Future Steps
por: Eken, Eda, et al.
Publicado: (2023)

Acceptability, Feasibility, and Utility of Integrating Pharmacogenetic Testing into a Child Psychiatry Clinic
por: Claudio‐Campos, Karla, et al.
Publicado: (2020)

Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients
por: Ramsey, Laura B., et al.
Publicado: (2020)

Design and Early Implementation Successes and Challenges of a Pharmacogenetics Consult Clinic
por: Arwood, Meghan J., et al.
Publicado: (2020)

Characterizing Pharmacogenetic Testing Among Children’s Hospitals
por: Brown, Jacob T., et al.
Publicado: (2020)

Perspectives from the Society for Pediatric Research: Pharmacogenetics for Pediatricians
por: Tang Girdwood, Sonya C., et al.
Publicado: (2022)

PREEMPTIVE PHARMACOGENETIC TESTING: EXPLORING THE KNOWLEDGE AND PERSPECTIVES OF UNITED STATES PAYERS
por: Keeling, Nicholas J., et al.
Publicado: (2017)

The landscape of pharmacogenetic testing in a US managed care population
por: Anderson, Heather D., et al.
Publicado: (2020)

Evaluating the Extent of Reusability of CYP2C19 Genotype Data among Patients Genotyped for Antiplatelet Therapy Selection
por: Beitelshees, Amber L., et al.
Publicado: (2020)

Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children
por: Aka, Ida, et al.
Publicado: (2017)

Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing
por: Van Driest, Sara L., et al.
Publicado: (2013)

Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands
por: Bank, P. C. D., et al.
Publicado: (2019)

Pharmacogenetic testing among patients with depression in a US managed care population
por: Anderson, Heather D., et al.
Publicado: (2022)

Development and Analytical Validation of a 29 Gene Clinical Pharmacogenetic Genotyping Panel: Multi‐Ethnic Allele and Copy Number Variant Detection
por: Scott, Stuart A., et al.
Publicado: (2020)

Exploring perceptions, knowledge, and attitudes regarding pharmacogenetic testing in the medically underserved
por: Gawronski, Brian E., et al.
Publicado: (2023)

97856 Implementation of DPYD and UGT1A1 pharmacogenetic testing to guide chemotherapy dosing
por: Varughese, Lisa A., et al.
Publicado: (2021)

Impact of Updating Pharmacogenetic Results: Lessons Learned from the PREDICT Program
por: Liu, Michelle, et al.
Publicado: (2021)

Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators
por: Cavallari, Larisa H., et al.
Publicado: (2022)

Implementation and utilization of genetic testing in personalized medicine
por: Abul-Husn, Noura S, et al.
Publicado: (2014)

Use of a multi-gene pharmacogenetic panel reduces adverse drug effects
por: Cavallari, Larisa H., et al.
Publicado: (2023)

Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population
por: Verma, Shefali S., et al.
Publicado: (2022)

Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients
por: Del Re, Marzia, et al.
Publicado: (2015)

CXCL5 polymorphisms are associated with variable blood pressure in cardiovascular disease-free adults
por: Beitelshees, Amber L, et al.
Publicado: (2012)

Establishment of a Pharmacogenetics Service Focused on Optimizing Existing Pharmacogenetic Testing at a Large Academic Health Center
por: Pasternak, Amy L., et al.
Publicado: (2020)

Pharmacogenetic testing in the Veterans Health Administration: Policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee
por: Vassy, Jason L., et al.
Publicado: (2018)

Variant Interpretation in Current Pharmacogenetic Testing
por: Luvsantseren, Sally, et al.
Publicado: (2020)

Prevalence and types of inconsistencies in clinical pharmacogenetic recommendations among major U.S. sources
por: Shugg, Tyler, et al.
Publicado: (2020)

Employment and ability to work after kidney transplantation in the Netherlands: The impact of preemptive versus non‐preemptive kidney transplantation
por: Visser, Annemieke, et al.
Publicado: (2022)

Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users
por: Chanfreau-Coffinier, Catherine, et al.
Publicado: (2019)

Cancer pharmacogenetics
por: Marsh, S, et al.
Publicado: (2004)

Pharmacogenetics of SGLT2 Inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker
por: Taylor, Simeon I., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pfarnc6ahpgiptqh6maa9i4odp